1,2,2,6,6-五甲基哌嗪 | 63867-56-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 1,2,2,6,6-五甲基哌嗪
• 英文名称: 1,2,2,6,6-Pentamethylpiperazine
• CAS: 63867-56-1
• 化学式: C₉H₂₀N₂
• 分子量: 156.27
• InChiKey: UILJIUFPKKZQQS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• METHOD FOR PRODUCING CARBOXYLIC ANHYDRIDE AND ARYLBORONIC ACID COMPOUND
  申请人：Ishihara Kazuaki

  公开号：US20110319620A1

  公开（公告）日：2011-12-29

  When phthalic acid is heated in heptane under azeotropic reflux conditions in the presence of a catalytic amount of an arylboronic acid compound (such as 2,6-(diisopropylaminomethyl)phenylboronic acid or 2,6-bis(diisopropylaminomethyl)phenylboronic acid), phthalic anhydride is obtained in high yield.

  当邻苯二甲酸在庚烷中，在存在催化量的芳基硼酸化合物（如2,6-(二异丙氨基甲基)苯硼酸或2,6-双(二异丙氨基甲基)苯硼酸）的条件下，进行共沸回流加热时，可以获得高产率的邻苯二甲酸酐。
• New pharmaceutical combinations for NOS inhibitors
  申请人：Pfizer Inc

  公开号：US20040229911A1

  公开（公告）日：2004-11-18

  The present invention relates to new pharmaceutical uses for compounds that exhibit activity as nitric oxide synthase (NOS) inhibitors. Specifically, it relates to the use of NOS inhibitors, particularly selective neuronal NOS (nNOS) inhibitors, alone or in combination with another active agent, in particular, either an SSRI or an NK-1 receptor antagonist, for the treatment of disorders or conditions the treatment which can be effected or facilitated by altering circadian rhythms. Examples of such disorders and conditions are blindness, obesity, seasonal affective disorder, bipolar disorder; jet lag, circadian sleep rhythms disorder, sleep deprivation, parasomnias, REM sleep disorders, hypersomnia, sleep-wake cycle disorders, narcolepsy and sleep disorders associated with shift work or irregular work schedules; nocturnal enuresis, and restless-legs syndrome.

  本发明涉及表现为一氧化氮合酶（NOS）抑制剂活性的化合物的新药物用途。具体地，涉及使用NOS抑制剂，特别是选择性神经元NOS（nNOS）抑制剂，单独或与另一种活性剂联合使用，特别是SSRI或NK-1受体拮抗剂，用于治疗可以通过改变昼夜节律来达到或促进治疗的疾病或病况。这些疾病和病况的例子包括失明、肥胖症、季节性情感障碍、双相情感障碍、时差反应、昼夜节律睡眠障碍、睡眠剥夺、睡眠障碍、REM睡眠障碍、嗜睡症、睡眠-觉醒周期障碍、嗜睡症和与轮班工作或不规则工作时间表相关的睡眠障碍、夜尿症和不宁腿综合症。
• Photochromic compositions
  申请人：LINTEC Corporation

  公开号：EP0467552B1

  公开（公告）日：1995-01-18
• TREATMENT OF VASCULAR LEAKAGE SYNDROME AND COLLAGENASE INDUCED DISEASE BY ADMINISTRATION OF MATRIX METALLOPROTEINASE INHIBITORS
  申请人：ONCOLOGIX, INC.

  公开号：EP0642353A1

  公开（公告）日：1995-03-15
• SELECTIVE INHIBITORS OF CONSTITUTIVE ANDROSTANE RECEPTOR
  申请人：ST. JUDE CHILDREN'S RESEARCH HOSPITAL

  公开号：US20170226115A1

  公开（公告）日：2017-08-10

  The compounds of the invention are antagonists of CAR, with specificity for CAR over other proteins including PXR. The disclosed compounds are useful in treating or controlling cell proliferative disorders, in particular oncological disorders, such as cancer. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.